EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSBSLG00000021822
Gene Symbol: CCKBR
3 Cross references
195 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSBSLG00000003536
Gene Symbol: LOC114846432
3 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSBSLG00000006064
Gene Symbol: LOC114849186
3 Cross references
259 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSBSLG00000006524
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSBSLG00000001811
Gene Symbol: CHRM2
3 Cross references
196 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBSLG00000019466
Gene Symbol: CHRM3
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBSLG00000013098
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSBSLG00000007965
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSBSLG00000020960
Gene Symbol: CHRM5
3 Cross references
190 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSBSLG00000020136
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBSLG00000016930
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSBSLG00000020129
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).